Latest news

• Novartis considers filings for PI3K drug in breast cancer

  own Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib).

• Daily Brief: DDF hits £250m investment, Hard Brexit could cost UK £100bn in trade and troublesome results for Pfizer’s Ibrance

  However, just weeks after Novartis released promising progressive-free survival data for Kisqali combo, Pfizer saw its drug flop in the same respect.

• FDA backs earlier use of Lilly’s breast cancer drug Verzenio

  year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’second-to-market CDK4/6 inhibitor Kisqali (ribociclib)). ... Kisqali made $35m in its first few months on the market after launches in the US and Europe in

• Novartis’ Promacta receives US breakthrough therapy designation

  The news comes hot on the heels of FDA breakthrough status for the company’s breast cancer drug Kisqali.

• Novartis bags new breakthrough status for Kisqali in breast cancer

  Novartis bags new breakthrough status for Kisqali in breast cancer. The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved. ... EvaluatePharma recently predicted that Ibrance will become a mega-blockbuster